Ichor Medical Systems pens AstraZeneca plasmid DNA delivery pact

The AstraZeneca pact comes after it penned vaccine deals with Pfizer and Janssen over the past few years. (AstraZeneca)

Following on the heels of Pfizer and Janssen, AstraZeneca has signed up to use Ichor Medical Systems’ platform aimed at delivering plasmid DNA into cells through electrical pulses.

The San Diego company has penned a collaboration and research license agreement with the Big Pharma, which focuses on the development and clinical assessment of plasmid DNA constructs.

So far, the TriGrid has been used across studies of both preventative and therapeutic DNA vaccines. “Improved vaccine potency with TriGrid delivery versus conventional injection, as well as induction of antibody and T cell responses, has been demonstrated in humans,” the company said in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: J&J partners with startup for DNA vaccine, hand-held device to treat HBV in $85M+ deal

But the AZ pact focuses on delivering DNA-encoding monoclonal antibodies directly into a person, after which that person’s own cells can begin to manufacture the antibodies.

Under the deal, these plasmids will encode monoclonal antibodies, developed by AZ, and will be delivered using Ichor’s TriGrid Delivery System, which uses electrical pulses sent to specific tissue sites, in order to boost plasmid DNA into cells.

Ichor gets upfront and annual payments, along with development milestones, but they are staying mum on the actual numbers involved.

“We are very excited to be working alongside AstraZeneca in this burgeoning field. Our goal is ultimately to increase access to antibody therapies for a wide range of disease indications affecting diverse global populations, thereby expanding new patient markets,” said Ichor CEO Bob Bernard.

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.